FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2275409689> ?p ?o ?g. }

• W2275409689 endingPage "353" @default.
• W2275409689 startingPage "343" @default.
• W2275409689 abstract "Abstract Low absolute lymphocyte count (ALC) to absolute monocyte count (AMC) ratio (ALC/AMC) is an independent prognostic factor in Hodgkin lymphoma (HL), but different cutoffs (1.1, 1.5, and 2.9) have been applied. We aimed to validate the prognostic significance of ALC/AMC in 537 homogenously treated (doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalents ± radiotherapy) classical HL patients at various cutoffs. The median ALC/AMC was 2.24 (0.44–20.50). The median AMC was 0.653 × 109/L (0.050–2.070). Lower ALC/AMC was associated with established markers of adverse prognosis. In total, 477 (89%), 418 (78%), and 189 (35%) patients had an ALC/AMC ratio of ≥1.1, ≥1.5, and ≥2.9; respectively; 20% had monocytosis (≥0.9 × 109/L). Ten-year time to progression (TTP) was 77% versus 55% for patients with ALC/AMC ≥1.1 and &lt;1.1 (p = .0002), 76% versus 68% for ALC/AMC ≥1.5 and &lt;1.5 (p = .049), 77% versus 73% for ALC/AMC ≥2.9 and &lt;2.9 (p = .35), and 79% versus 70% for ALC/AMC ≥2.24 and &lt;2.24 (p = .08), respectively. In stages ΙΑ/ΙΙΑ and in patients ≥60 years old, ALC/AMC had no significant effect on TTP. In advanced stages, ALC/AMC was significant only at the cutoff of 1.1 (10-year TTP 67% vs. 48%; p = .016). In younger, advanced-stage patients, the differences were more pronounced. In multivariate analysis of TTP, ALC/AMC &lt; 1.1 (p = .007) and stage IV (p &lt; .001) were independent prognostic factors; ALC/AMC was independent of International Prognostic Score in another model. ALC/AMC was more predictive of overall survival than TTP. At the cutoff of 1.1, ALC/AMC had independent prognostic value in multivariate analysis. However, the prognostically inferior group comprised only 11% of patients. Further research is needed prior to the widespread use of this promising marker." @default.
• W2275409689 created "2016-06-24" @default.
• W2275409689 creator A5004798691 @default.
• W2275409689 creator A5008871172 @default.
• W2275409689 creator A5015064359 @default.
• W2275409689 creator A5018471960 @default.
• W2275409689 creator A5018858121 @default.
• W2275409689 creator A5021836607 @default.
• W2275409689 creator A5025768647 @default.
• W2275409689 creator A5033750115 @default.
• W2275409689 creator A5036299617 @default.
• W2275409689 creator A5039544898 @default.
• W2275409689 creator A5041806045 @default.
• W2275409689 creator A5044462260 @default.
• W2275409689 creator A5048284508 @default.
• W2275409689 creator A5051484617 @default.
• W2275409689 creator A5052212457 @default.
• W2275409689 creator A5064540712 @default.
• W2275409689 creator A5064642096 @default.
• W2275409689 creator A5064804661 @default.
• W2275409689 creator A5068927620 @default.
• W2275409689 creator A5070690484 @default.
• W2275409689 creator A5075599693 @default.
• W2275409689 creator A5077500157 @default.
• W2275409689 creator A5078995254 @default.
• W2275409689 creator A5080629810 @default.
• W2275409689 creator A5087415952 @default.
• W2275409689 creator A5090960123 @default.
• W2275409689 date "2016-02-26" @default.
• W2275409689 modified "2023-09-26" @default.
• W2275409689 title "Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens" @default.
• W2275409689 cites W1596519391 @default.
• W2275409689 cites W1896341258 @default.
• W2275409689 cites W1976510049 @default.
• W2275409689 cites W1984132561 @default.
• W2275409689 cites W1993818414 @default.
• W2275409689 cites W1996764137 @default.
• W2275409689 cites W1997474334 @default.
• W2275409689 cites W2004340977 @default.
• W2275409689 cites W2008904517 @default.
• W2275409689 cites W2010746974 @default.
• W2275409689 cites W2012273917 @default.
• W2275409689 cites W2018076768 @default.
• W2275409689 cites W2018588463 @default.
• W2275409689 cites W2032111423 @default.
• W2275409689 cites W2034400622 @default.
• W2275409689 cites W2045001700 @default.
• W2275409689 cites W2048749905 @default.
• W2275409689 cites W2059677602 @default.
• W2275409689 cites W2065755146 @default.
• W2275409689 cites W2068693591 @default.
• W2275409689 cites W2070320237 @default.
• W2275409689 cites W2074817164 @default.
• W2275409689 cites W2078346532 @default.
• W2275409689 cites W2087366892 @default.
• W2275409689 cites W2101873015 @default.
• W2275409689 cites W2109218540 @default.
• W2275409689 cites W2115919161 @default.
• W2275409689 cites W2116294985 @default.
• W2275409689 cites W2123981364 @default.
• W2275409689 cites W2125616358 @default.
• W2275409689 cites W2125790189 @default.
• W2275409689 cites W2131358677 @default.
• W2275409689 cites W2133201432 @default.
• W2275409689 cites W2134487676 @default.
• W2275409689 cites W2136962826 @default.
• W2275409689 cites W2139984188 @default.
• W2275409689 cites W2156755241 @default.
• W2275409689 cites W2161513792 @default.
• W2275409689 cites W2289689792 @default.
• W2275409689 cites W2328676772 @default.
• W2275409689 cites W4293241248 @default.
• W2275409689 doi "https://doi.org/10.1634/theoncologist.2015-0251" @default.
• W2275409689 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4786349" @default.
• W2275409689 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26921291" @default.
• W2275409689 hasPublicationYear "2016" @default.
• W2275409689 type Work @default.
• W2275409689 sameAs 2275409689 @default.
• W2275409689 citedByCount "21" @default.
• W2275409689 countsByYear W22754096892016 @default.
• W2275409689 countsByYear W22754096892017 @default.
• W2275409689 countsByYear W22754096892018 @default.
• W2275409689 countsByYear W22754096892019 @default.
• W2275409689 countsByYear W22754096892020 @default.
• W2275409689 countsByYear W22754096892021 @default.
• W2275409689 countsByYear W22754096892022 @default.
• W2275409689 crossrefType "journal-article" @default.
• W2275409689 hasAuthorship W2275409689A5004798691 @default.
• W2275409689 hasAuthorship W2275409689A5008871172 @default.
• W2275409689 hasAuthorship W2275409689A5015064359 @default.
• W2275409689 hasAuthorship W2275409689A5018471960 @default.
• W2275409689 hasAuthorship W2275409689A5018858121 @default.
• W2275409689 hasAuthorship W2275409689A5021836607 @default.
• W2275409689 hasAuthorship W2275409689A5025768647 @default.
• W2275409689 hasAuthorship W2275409689A5033750115 @default.
• W2275409689 hasAuthorship W2275409689A5036299617 @default.
• W2275409689 hasAuthorship W2275409689A5039544898 @default.
• W2275409689 hasAuthorship W2275409689A5041806045 @default.

• next